Actually, I think I said third rate, in which category I would include Rodman. Of Leerink, I know nothing.
This article is as goofy as many of the others. It does not note the real achievement of Vertex, while hyping very early phase studies that are years behind Vertex and trying to mind read the FDA.
The Roche study reports are only as of 4 weeks and while they did note that there were discontinuations, they did not give any numbers. You call Vertex for hyping, perhaps, but I have witnessed them be very thorough in the data they release, unlike Roche. So, what can you really make of the Roche study other than Roche may or may not have something, but is two years behind Vertex.
The Medivir results were from a Phase 1 study. How much competitive threat do you glean from a Phase 1 study?
I am not impressed with the reporting on the HCV developments coming out of AASLD. It seems quite incompetent. If you relied only on those reports and didn't do some thorough dd, certainly you would dump your shares. But you can also take this as an opportunity to pick up some cheap shares.
Market Data 
Markets 
AI
